跳至主要内容
临床试验/CTRI/2025/08/093651
CTRI/2025/08/093651尚未招募不适用

Effect of endobronchial administration of Colistin on outcomes in patients with Ventilator Associated Pneumonia: a randomized controlled study

ALL INDIA INSTITUTE OF MEDICAL SCIENCES,RISHIKESH1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2025年10月1日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
80
试验地点
1
主要终点
To compare ventilator free days

研究概览

简要总结

VAP refers to pneumonia that arises more than Pneumonia has been defined as an acute infection of the pulmonary parenchyma. Pneumonia was defined by ATS/IDSA (2016) criteria clinically as the presence of “new lung infiltrate plus clinical evidence that the infiltrate is of an infectious origin, which include the new onset of fever, purulent sputum, leukocytosis, and decline in oxygenation”.Pneumonia is the eighth leading cause of death and first among infectious causes of death. The mortality rate is as high as 23% for patients admitted to the intensive care unit for severe pneumonia.

The symptoms of pneumonia include fever with chills, cough with expectoration, pleuritic chest pain, malaise, loss of appetite, myalgia. Some patients may have an altered mental status, abdominal pain and other systemic findings. Infiltrates on chest radiograph or computed tomography scan, total and differential leucocyte count, sputum gram stain, sputum culture and sensitivity and blood culture are the investigations which aids to diagnose pneumonia. Procalcitonin and C-Reactive Protein (CRP) are used to differentiate between bacterial and viral pneumonia.

Pneumonia has been classified into the following by American Thoracic Society:

1.Community Acquired Pneumonia (CAP)

  1. Hospital Acquired Pneumonia (HAP)

3.Ventilator Associated Pneumonia (VAP)

48 hours after endotracheal intubation. Ventilator-associated pneumonia (VAP) is one of the most frequent ICU-acquired infections. A data suggests that approximately 10% of patients who required mechanical ventilation were diagnosed with VAP.All-cause mortality associated with VAP ranges from 20% to 50% while attributable mortality is 13%.

The Clinical Pulmonary Infection Score (CPIS) is a tool used to assess the likelihood of ventilator-associated pneumonia (VAP) in mechanically ventilated patients. CPIS score include the following: tracheal secretions, chest x-ray infiltrates, temperature, leukocytes count, P/F ratio. CPIS score of >6 is highly suggestive of ventilator associated pneumonia in the clinical setting.  Modified CPIS score includes microbiological culture also. LUPPIS score also includes Lung Ultrasound in place of chest x-ray and Pentraxin-3 (PTX-3). ATS guidelines recommend noninvasive sampling of respiratory secretions with semi-quantitative cultures for the diagnosis of VAP.

To date there is scarcity of literature regarding the efficacy of endobronchial instillation of colistin in ventilator associated pneumonia patients. Therefore, we plan to conduct this study to evaluate the effect of endobronchial instillation of colistin on outcomes in patients with ventilator associated pneumonia

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 80.00 Year(s)(—)
性别
All

入选标准

  • 1.Patients both male and female aged more than 18 years 2.Diagnosed as ventilator associated pneumonia with a CPIS score of more than 6 3.Culture positive for organisms with intermediate sensitivity to Colistin
  • Intubated on Ventilator support.

排除标准

  • 1.Patients/next of Kin refusal to consent.
  • 2.Patients with Multiple Organ Dysfunction Syndrome (MODS),septic shock at the beginning of the study.
  • 3.Patients with a P/F (PaO2/FiO2) ratio below 100 4.Patients with severe COPD more than Grade GOLD 3E 5.Patients with recent myocardial infarction within 6 months or Heart failure with reduced Ejection Fraction (HFrEF) with Ejection Fraction (EF) less than 40 percentage 6.Immunodeficient patients 7.History of allergy to Colistin 8.Patients with infections resistant to Colistin.

结局指标

主要结局

To compare ventilator free days

时间窗: till day 28

次要结局

  • CPIS score(Day 7)
  • CPIS score less than 6(till day 7)
  • To compare the mortality between the two groups(within 28 days)
  • To compare the length of ICU-stay between the two groups(till day 28)
  • To compare the length of hospital-stay between the two groups(till day 28)
  • adverse effects(till 3 days)

研究者

发起方
ALL INDIA INSTITUTE OF MEDICAL SCIENCES,RISHIKESH
申办方类型
Research institution and hospital
责任方
Principal Investigator
主要研究者

Dr Arvinth V S

AIIMS RISHIKESH

研究点 (1)

Loading locations...

相似试验